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Abstract: Hyperemesis gravidarum is a complex condition with a multifactorial etiology 
characterized by severe intractable nausea and vomiting. Despite a high prevalence, studies 
exploring underlying etiology and treatments are limited. We performed a literature review, 
focusing on articles published over the last 10 years, to examine current perspectives and recent 
developments in hyperemesis gravidarum.
Keywords: hyperemesis gravidarum, nausea, vomiting in pregnancy, pregnancy, antiemetics, 
adverse pregnancy outcomes
Introduction
Up to 80% of all pregnant women experience some form of nausea and vomiting 
during their pregnancy.1–3 The International Statistical Classification of Disease and 
Related Health Problems, Tenth Revision, defines hyperemesis gravidarum (HG) as 
persistent and excessive vomiting starting before the end of the 22nd week of gestation 
and further subdivides the condition into mild and severe, with severe being associated 
with metabolic disturbances such as carbohydrate depletion, dehydration, or electrolyte 
imbalance.4 HG is a diagnosis of exclusion, characterized by prolonged and severe 
nausea and vomiting, dehydration, large ketonuria, and more than 5% body weight 
loss.5,6 Affecting approximately 0.3%–2.0% of pregnancies, HG is the commonest 
indication for admission to hospital in the first half of pregnancy and is second only 
to preterm labor as a cause of hospitalization during pregnancy.7–9
According to the Hyperemesis Education and Research Foundation, conservative 
estimates indicate that HG can cost a minimum of $200 million annually in in-house 
hospitalizations in the United States.10 Taking into account other factors such as emer-
gency department treatments, potential complications of severe HG, and the fact that 
up to 35% of women with paid employment will lose time from work through nausea, 
the actual cost of HG to the economy is significantly higher.3 In a related economic 
analysis, Piwko et al projected that the United States spends nearly $2 billion in costs 
attributed to pregnancy-related nausea and vomiting; 60% of this expenditure is a 
result of direct costs (eg, drugs, hospital admission), and 40% is a result of indirect 
costs (eg, time lost from work).11
To date, studies investigating the association between HG and adverse pregnancy 
outcomes and maternal morbidities have provided conflicting results.9,12 In all aspects 
of research involving HG, the interpretation of results and associations must be 
with caution, as the majority of the studies have been limited by retrospective study 
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design,10,13–15 small numbers,16 bias, lack of control for poten-
tial confounders, and variable definitions of HG.15,17,18
Thus, to examine current clinical perspectives of HG, 
we performed a review of MEDLINE (1994–January 2014), 
EMBASE (1994–January 2014), and the Cochrane Library. 
Articles related to “hyperemesis gravidarum” and/or “nausea 
and vomiting of pregnancy” were considered for inclusion in 
our review. Reference lists of selected articles were reviewed 
to identify additional articles. Although the review focused on 
articles published in the last 10 years, a second search with 
unrestricted time limits was performed to identify key papers 
related to HG that were also considered in the review.
Risk factors for HG
HG is most likely a multifactorial condition and has been 
associated with many risk factors.19 Women with HG are more 
likely to be younger, primiparous, persons of color, and less 
likely to drink alcohol.20,21 Body mass index, smoking, and 
socioeconomic status do not appear to differ significantly 
between women with HG and those without.21 Female infant 
sex has also been associated with HG.8,22–25 Paternal genes are 
not thought to play a role in the occurrence of HG. In contrast, 
maternal intergenerational effects have been observed, with 
increased odds of HG among women whose mothers also 
experienced HG during a previous pregnancy (unadjusted 
odds ratio [OR], 3.2; 95% confidence interval [CI], 1.6–6.4).26 
Moreover, although recurrence rates are higher in women 
with HG, they are not 100%, indicating a multifactorial 
process rather than purely maternal genetics.27,28
In a small pilot study, D’Orazio et al examined personality 
characteristics between 15 women with HG and 15 matched 
women without HG and did not detect any differences in 
personality, psychological, or somatic variables.29 Mullin 
et al examined risk factors in 395 women with prolonged HG. 
Women with prolonged HG were slightly younger and 
weighed more and had a history of allergies and a restrictive 
diet.30 Of those women with HG with a significant weight 
loss (.15% of prepregnancy weight), HG tended to be more 
severe, with some symptoms, such as food aversion, continu-
ing through the postpartum period.14 Ethnicity may play a role, 
with one study in Germany demonstrating that immigrants 
were 4.5 times more likely to be treated for HG than native 
Germans. These women also scored higher on a somatization 
scale (Symptom Checklist-90-Revised), indicating a higher 
degree of “psychological distress”.31 Asian ethnicity has also 
been reported as a risk factor.32
One observational study demonstrated that women with 
HG were more likely to have higher levels of pregnancy-
associated plasma protein A (PAPP-A) and free human 
chorionic gonadotropin (hCG) in the first trimester compared 
with controls.34 Maternal serum concentrations of hCG peak 
during the first trimester, when HG symptoms are often at 
their worst.35 Similarly, symptoms of HG are often more 
severe in multiple pregnancies and molar pregnancies, 
which are conditions associated with excessively high hCG 
levels. However, conflicting reports exist,34–36 and therefore a 
causal association between HG and hCG has not been estab-
lished.36 Infection with Helicobacter pylori may play a role 
in the development of HG in some women. A meta-analysis 
examining H. pylori infection in women with HG reported a 
significant association (OR, 3.32; 95% CI, 2.25–4.90).37 The 
meta-analysis was limited by significant heterogeneity among 
studies. Therefore, similar to hCG, a causal association 
between HG and H. pylori has not been established. Other 
factors implicated in the etiology of HG include estrogen,38 
stress, depression, and anxiety.21
HG and adverse fetal  
pregnancy outcomes
HG has been reported to be associated with an increased risk 
for adverse pregnancy outcomes such as low birth weight, 
preterm birth, and small-for-gestational age infants.10,13,25 
A recent systematic review identified no association with 
Apgar scores, congenital anomalies, or perinatal death.25
Several additional studies were not included in the 
aforementioned review either because of inclusion criteria 
or because of publication after the review search period. 
McCarthy et al performed a prospective cohort study of 
3,423 nulliparous women.21 HG was defined as repeated 
vomiting in early pregnancy not resulting from other causes 
(eg, gastroenteritis) and requiring any of the following: 
inpatient admission, day stay with intravenous fluids, 
nasogastric feeding (at home or in hospital), or vomiting 
associated with loss of more than 5% of her booking weight. 
Women with hospitalized HG were considered as having 
severe HG. Secondary outcomes included spontaneous pre-
term birth, preeclampsia, birthweight, small-for-gestational 
age infants, and infant sex ratio. Women with severe HG had 
an increased risk of having a spontaneous preterm birth com-
pared with women without HG (adjusted OR, 2.6; 95% CI, 
1.2–5.7).21 No significant associations were observed among 
other secondary outcomes.
Other studies have reported conflicting results. Vikanes 
et al conducted a retrospective cohort study and identified 
814 women with HG during a 10-year period in Norway.39 
Relative to women without HG, no increased risk for adverse 
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pregnancy outcomes or low birthweight was observed among 
women with HG. Vandraas et al conducted a population-
based cohort study of 2,270,363 births between 1967 and 
2009, using the Norwegian Birth Registry.40 They reported 
a decreased odds of very preterm birth (OR, 0.66; 95% CI, 
0.5–0.9) and large-for-gestational-age infants (OR, 0.9: 
95% CI, 0.8–0.9) among women diagnosed with HG. 
Hastoy et al reviewed obstetric outcomes in a small cohort 
of 197 women hospitalized for HG in a tertiary maternity 
hospital in France.41 Similar to Vikanes et al,39 no significant 
associations were observed between HG and adverse perina-
tal outcomes. However, in contrast, Hastoy et al did observe 
an increased risk for low birth weight (adjusted relative risk 
[RR], 1.7; 95% CI, 1.1–2.4).41
Fejzo et al performed a study involving 819 women from 
an HG Web site registry: 16% of babies were born prema-
turely, and 8% of the women reported infants born weighing 
less than 2,500 g.14 Among women with extreme weight loss, 
9.3% reported having a child with a behavioral disorder. As 
with other research in HG, the lack of a robust control group 
makes these results difficult to interpret. Still, similar results 
have been reported in women with extreme starvation, sug-
gesting similar underlying pathological processes.42
There is a paucity of data examining the long-term effects 
of HG throughout childhood and into adulthood.25 In a retro-
spective case-control study of 259 adults, psychological and 
behavioral disorders were more frequently reported among 
adults exposed to HG in utero (OR, 3.6; 95% CI, 1.9–6.9).43 
Notably, this risk estimate was based on a composite out-
come of 17 different disorders because of small numbers 
for the majority of diagnoses under review (often ,5 cases 
observed per individual disorder). Nonetheless, individual 
analyses of anxiety, depression, and bipolarism revealed no 
increased odds of anxiety; though in contrast, increased odds 
of depression and bipolarism were observed. Although other 
research has reported an increased risk for psychological dis-
orders in adulthood, as well as reduced insulin sensitivity in 
prepubertal children,44 prospective longitudinal investigations 
are warranted to better understand the underlying dynamics 
of these associations.45
HG and adverse maternal outcomes
HG can be extremely debilitating for women and, if inad-
equately managed, can cause significant morbidities, includ-
ing malnutrition and electrolyte imbalances, thrombosis, 
Wernicke’s encephalopathy, depressive illness, and poor 
pregnancy outcomes such as prematurity and small-for-
gestational-age fetuses.13,46–49 Mullin et al showed that those 
with HG were more likely to suffer from hematemesis, 
dizziness, fainting, and antiemetic treatment.30 Bolin et al 
observed that women with HG have an increased risk for 
placental disorders, such as placental abruption, and that this 
risk was particularly marked among women presenting with 
HG in the second trimester.50
Furthermore, after pregnancy, these women were more 
likely to develop posttraumatic stress disorder, motion 
sickness, and muscle weakness and to have infants with 
colic, irritability, and growth restriction.30 Jørgensen et al33 
demonstrated that the risk for any autoimmune disorder 
was significantly increased in women with HG (RR, 1.41; 
95% CI, 1.30–1.51). In its extreme forms, HG may cause 
malnutrition and end organ damage manifesting as oliguria 
and abnormal liver function tests. Reassuringly, permanent 
hepatic damage and associated death are rare in women 
with HG.51
In their large, prospective study on women with HG, 
McCarthy et al demonstrated that women with HG, particu-
larly severe HG, were at increased risk for cognitive, behav-
ioral, and emotional dysfunction in pregnancy.21 Other studies 
have linked HG with an increased risk for depression, anxiety, 
and mental health difficulties,52,53 and as a result, some advo-
cate psychiatric evaluation.54 One study reported women with 
HG meet criteria for anxiety and depression in 47% and 48% 
of cases, respectively.12 Despite such associations, care must 
be taken not to stigmatize the condition of HG.
Identification and treatment of HG
It is important to emphasize that early assessment of nausea 
and vomiting in pregnancy is essential to prevent delay in 
diagnosis and management of HG. Apart from HG, consid-
eration should be given to other underlying complications 
associated with persistent vomiting, such as gastrointes-
tinal conditions (eg, hepatitis, pancreatitis, or biliary tract 
 disease), pyelonephritis, and metabolic disorders (eg, diabetic 
ketoacidosis, porphyria, or Addison’s disease).55 If such 
conditions are ruled out, adherence to obstetrical guidelines 
for the management of nausea and vomiting in pregnancy 
is encouraged,55–58 although disconcertingly, this may not 
always be followed in practice.59
Notably, diagnostic biomarkers for HG have produced 
inconsistent results. A recent systematic review and meta-
analysis found that although ketonuria is often assessed as 
part of a clinical examination, the robustness of ketonuria 
as a diagnostic marker for HG remains unclear.60 Future 
investigations examining ketonuria levels in the diagnosis and 
severity of HG are warranted. Lymphocytes were typically 
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higher in women presenting with HG, although the associa-
tion between HG and hCG and thyroid hormones, leptin, 
estradiol, progesterone, and white blood count were less 
reliable.60 As previously discussed, H. pylori serology may 
be of diagnostic benefit.60
Treatment strategies for HG include inpatient and out-
patient care involving intravenous fluids, antiemetics, and 
dietary advice. Care for women with HG centers around 
early intervention and support. A lack of support may pre-
vent women from accessing timely and appropriate care.61 
A recently published systematic review involving 37 trials 
and 5,049 women investigated interventions for the treat-
ment for HG. Interventions examined included acupressure, 
acustimulation, acupuncture, ginger, chamomile, lemon oil, 
mint oil, vitamin B6, and several antiemetic drugs. Again, 
the review was significantly limited by heterogeneity in study 
participants, interventions, comparison groups, and outcomes 
measured or reported. Acupuncture showed no significant 
benefit to women in pregnancy. Ginger may have some ben-
efits, but the evidence was limited.  Pharmacological agents 
including vitamin B6 and antiemetic drugs may help relieve 
mild or moderate nausea and vomiting.62  Administration of 
promethazine and metoclopramide may yield comparable 
therapeutic effects.63 Although research is limited, preemp-
tive treatment with Diclectin (Duchesnay, Blainville, Québec, 
Canada) in women with a history of severe nausea and vomit-
ing in pregnancy may decrease the onset of HG.64 Overall, 
however, evidence is lacking as to which pharmacological 
agent is more effective and less dangerous to both mother 
and fetus.62,65–68
The management of HG is therefore based on correcting 
electrolyte imbalance and dehydration, prophylaxis against 
recognized complications, and providing symptomatic relief. 
Tan et al randomized women with HG to either treatment 
with 5% dextrose saline or normal saline for rehydration. 
Outcomes were resolution of ketonuria and the woman’s well-
being.69 Short-term benefits (,24 hours) were observed in 
those treated with 5% dextrose, but these had dissipated by 
24 hours. There is an understandable reluctance to prescribe 
antiemetics for symptomatic relief, but extensive data exist 
to show a lack of teratogenesis with dopamine antagonists, 
phenothiazines, and histamine H1 receptor blockers.70–72 
Although most women respond well to rehydration, if 
necessary, enteral tube feeding may be initiated to serve as 
either as a supplemental or primary source of nutrition.73 
Consideration may also be given to total parenteral nutri-
tion, although increased risk for infectious complications is 
a potential concern.73,74
Day care has proven to be a beneficial and safe mode 
of care for women in other clinical settings.75 Studies have 
demonstrated that day care management of women with 
nausea and vomiting during pregnancy appears acceptable 
and feasible,76 but no systematic reviews or randomized con-
trolled trials have been performed that examine the effects of 
introducing day care on rates of hospital admission, duration 
of inpatient stay, and patient satisfaction.
Potential research topics  
and interventions
A randomized controlled trial comparing day patient and 
inpatient management has finished recruiting approximately 
100 women and will soon publish its findings.77 Further 
studies are needed that focus on safe alternative treatments, 
preventative measures in high-risk women, new biomarkers 
underlying the etiology of HG, and interventions that may 
reduce adverse pregnancy outcomes.
Further research is also required to determine whether 
the provision of emotional support for women with HG 
is beneficial. Although studies are limited in this area, in 
general, there is a demand for support for women suffering 
from nausea and vomiting in pregnancy.51 As shown in a 
recent study evaluating a nausea and vomiting in pregnancy 
hotline in the United States, women primarily seek support 
in the management of the nausea and vomiting as well as 
understanding drug risks for the fetus.78 Given that much of 
the information available on the Internet uses complicated 
language, there is a clear need to improve Web resources 
for HG; this may be a complementary strategy to providing 
support for women.79 Any new interventions, however, must 
be shown to be safe from both a maternal and fetal point of 
view, to be acceptable to mothers, and to be cost-effective.
Conclusion
Despite the prevalence and considerable morbidity associated 
with HG, good-quality research investigating the underlying 
etiology and interventions to treat and prevent HG remains 
scarce. Exploring new pharmacological interventions in 
pregnant women for the prevention and treatment of HG 
remains elusive, and this may be a result of avoiding induc-
ing unnecessary risk for the developing fetus. Controversies 
such as that involving the administration of thalidomide to 
women with morning sickness, which subsequently resulted 
in significant congenital malformations, has likely discour-
aged researchers from investigating other interventions for 
HG.80 As a result, the current mainstay of treatment remains 
regular hydration and antiemetics. Nonetheless, because of 
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the prevalence and morbidity associated with this condition, 
safe, well-conducted, good-quality research is needed to 
investigate and clarify the etiology, prevention, and treatment 
of this condition.
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